ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
bioAffinity Technologies, Inc. (BIAF) stock declined over -18.35%, trading at $0.89 on NASDAQ, down from the previous close of $1.09. The stock opened at $0.90, fluctuating between $0.83 and $1.07 in the recent session.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Employees | 75 |
Beta | 3.14 |
Sales or Revenue | $2.53M |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Diagnostics & Research |